Pharmaceutical Biotechnology

1. Monoclonal Antibodies and Antibody-Based Biotherapeutics in Inflammatory Diseases

   • Honghui Zhou, Zhenhua Xu, Mary Ann Mascelli, Hugh M. Davis

   Pages 393-412

2. Interferons and Interleukins

   • Jean-Charles Ryff, Sidney Pestka

   Pages 413-437

3. Vaccines

   • Wim Jiskoot, Gideon F. A. Kersten, Enrico Mastrobattista

   Pages 439-457

4. Oligonucleotides

   • Raymond M. Schiffelers, Enrico Mastrobattista

   Pages 459-475

5. Gene Therapy

   • Hao Wu, Ram I. Mahato

   Pages 477-507

6. Stem Cell Technology

   • Colin W. Pouton

   Pages 509-524

7. Back Matter

   Pages 525-544

   PDF

This introductory text explains both the basic science and the applications of biotechnology-derived pharmaceuticals, with special emphasis on their clinical use. It serves as a complete one-stop source for undergraduate/graduate pharmacists, pharmaceutical science students, and for those in the pharmaceutical industry. The Fourth Edition will completely update the previous edition, and will also include additional coverage on the newer approaches such as oligonucleotides, siRNA, gene therapy and nanotech.

• Formulation development
• Immunogenicity
• Molecular biology
• Nucleotide-based therapeutics
• Pharmacokinetics and pharmacodynamics
• Protein therapeutics

• Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

  Daan J. A. Crommelin

• Department of Pharmaceutical Sciences and Department of Medicine, The University of British Columbia, Vancouver, Canada

  Robert D. Sindelar

• Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, College of Pharmacy, Memphis, USA

  Bernd Meibohm

DAAN J.A. CROMMELIN is Professor at the Department of Pharmaceutics at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Dr. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical product formulations and advanced drug delivery systems. He published over 335 articles and has held leadership positions at the International Pharmaceutical Federation (FIP) and the European Federation for Pharmaceutical Sciences (EUFEPS).

ROBERT D. SINDELAR is currently President, The Providence Health Care Research Institute, Vice President Research and Academic, Providence Health Care (part of the British Columbia public health care system), Professor Faculty of Pharmaceutical Sciences and Associate Dean Research Faculty of Medicine The University of British Columbia (UBC).  He served for 11 years as Dean and Professor, The UBC Faculty of Pharmaceutical Sciences following 19 years at the University of Mississippi where he held the positions of Professor and Chair of Medicinal Chemistry, School of Pharmacy and served as Interim Dean.  Dr. Sindelar’s expertise lies in medicinal chemistry, computer-aided drug discovery and design, pharmaceutical biotechnology, and creating opportunities to integrate innovation into the health care system. 

BERND MEIBOHM is Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the University of Tennessee College of Pharmacy in Memphis. His area of expertise lies in clinical pharmacology and pharmacokinetic/pharmacodynamics correlations. Dr. Meibohm obtained his doctoral degree in Pharmaceutics from the Technical University Carolo-Wilhelmina, Braunschweig, Germany and received postdoctoral training at the University of Florida, Gainesville. Dr. Meibohm is a fellow of the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology, and has published three textbooks, more than 90 peer-reviewed research articles and book chapters, 130 abstracts, and over 100 invited scientific presentations to national and international audiences.

Policies and ethics